Amber Bio’s proprietary platform leverages multi-kilobase RNA editing and AI foundation models to expand the reach of treatable pathogenic variants SAN FRANCISCO--(BUSINESS WIRE)--Amber Bio, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results